Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the supplemental ...

BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower ...

Regeneron Pharmaceuticals ( NASDAQ: REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ( (sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...

Dodge & Cox slightly bumped up its stake in Regeneron Pharmaceuticals, now holding a cool $1.65 billion in shares. This minor 0.4% increase added just 9,381 shares but upped their ownership to 2.11%.